Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.

Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M

Clinical endocrinology7 Jun 2007Cited by 52 (Europe PMC)

PMID17555511DOI10.1111/j.1365-2265.2007.02917.xPepBankPUB-17555511

Publisher page PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanNon-randomized trialOther
In patients with acromegaly receiving lanreotide Autogel, one patient withdrew before dose adjustment.
In plain wordsIn patients with acromegaly receiving lanreotide Autogel, one patient withdrew before dose adjustment.
Peptide
Lanreotide
Outcome
Not applicableTreatment withdrawal before dose adjustment
Study
n = 23
Outcome group
Treatment adherence and retention · Whole body
Studied dose
120 mg every 6 weeks · deep subcutaneous injectionAs given in this study (human).
Measurements
Patients withdrawn before dose adjustment
1 patients
ATG120 group
Source sentences
Summary
The frequency of ATG120 administrations was adjusted to every 4 weeks in 12 patients, every 6 weeks in 4 patients and every 8 weeks in 6 patients; 1 patient withdrew before the dose adjustment.
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551115
02HumanNon-randomized trialEfficacy outcome
In acromegaly patients, lanreotide reduced GH from 9.9 +/- 11.3 to 3.5 +/- 5.7 at Period 1 (P < 0.01).
In plain wordsIn acromegaly patients, lanreotide reduced GH from baseline at Period 1.
Peptide
Lanreotide
Outcome
DecreaseGH during Period 1
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 6 weeks for four injections · deep subcutaneous injectionAs given in this study (human).
Measurements
Mean GH at baseline (Visit 1)
9.9 microg/l
+/- 11.3, type not stated
Mean GH at end of Period 1
3.5 microg/l
+/- 5.7, type not stated
P value
< 0.01
versus baseline
Source sentences
Summary
ATG120 induced a significant GH decrease from 9.9 +/- 11.3 at baseline (Visit 1) to 3.5 +/- 5.7 at the end of Period 1 (P < 0.01) and to 3.8 +/- 5.7 microg/l at the final visit (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551101
03HumanNon-randomized trialEfficacy outcome
In acromegaly patients, lanreotide reduced GH to 3.8 +/- 5.7 microg/l at the final visit (P < 0.01).
In plain wordsIn acromegaly patients, lanreotide reduced GH from baseline at the final visit.
Peptide
Lanreotide
Outcome
DecreaseGH at final visit
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 4-8 weeks · deep subcutaneous injectionAs given in this study (human).
Measurements
Mean GH at baseline (Visit 1)
9.9 microg/l
+/- 11.3, type not stated
Mean GH at final visit
3.8 microg/l
+/- 5.7, type not stated
P value
< 0.01
versus baseline
Source sentences
Summary
ATG120 induced a significant GH decrease from 9.9 +/- 11.3 at baseline (Visit 1) to 3.5 +/- 5.7 at the end of Period 1 (P < 0.01) and to 3.8 +/- 5.7 microg/l at the final visit (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551102
04HumanNon-randomized trialEfficacy outcome
In acromegaly patients, lanreotide reduced IGF-I from 544 +/- 312 to 318 +/- 181 microg/l at Period 1 (P < 0.05).
In plain wordsIn acromegaly patients, lanreotide reduced IGF-I from baseline at Period 1.
Peptide
Lanreotide
Outcome
DecreaseIGF-I during Period 1
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 6 weeks for four injections · deep subcutaneous injectionAs given in this study (human).
Measurements
Mean IGF-I at baseline (Visit 1)
544 microg/l
+/- 312, type not stated
Mean IGF-I at end of Period 1
318 microg/l
+/- 181, type not stated
P value
< 0.05
versus baseline
Source sentences
Summary
IGF-I also decreased from 544 +/- 312 at baseline (Visit 1) to 318 +/- 181 at Period 1 and to 356 +/- 187 microg/l at the final visit (both P < 0.05 vs. baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551103
05HumanNon-randomized trialEfficacy outcome
In acromegaly patients, lanreotide reduced IGF-I to 356 +/- 187 microg/l at the final visit (P < 0.05).
In plain wordsIn acromegaly patients, lanreotide reduced IGF-I from baseline at the final visit.
Peptide
Lanreotide
Outcome
DecreaseIGF-I at final visit
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 4-8 weeks · deep subcutaneous injectionAs given in this study (human).
Measurements
Mean IGF-I at baseline (Visit 1)
544 microg/l
+/- 312, type not stated
Mean IGF-I at final visit
356 microg/l
+/- 187, type not stated
P value
< 0.05
versus baseline
Source sentences
Summary
IGF-I also decreased from 544 +/- 312 at baseline (Visit 1) to 318 +/- 181 at Period 1 and to 356 +/- 187 microg/l at the final visit (both P < 0.05 vs. baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551104
06HumanNon-randomized trialEfficacy outcome
In acromegaly patients, GH with lanreotide at both assessment periods was similar to GH with octreotide LAR.
In plain wordsIn acromegaly patients, GH with lanreotide was similar to GH with octreotide LAR.
Peptide
Lanreotide
Outcome
Direction not reportedGH versus octreotide
Study
n: not reported in source
Comparator
octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 4-8 weeks · deep subcutaneous injectionAs given in this study (human).
Source sentences
Summary
Serum GH and IGF-I achieved at the end of Period 1 and Period 2 were similar to those reached with o-LAR.
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551105
07HumanNon-randomized trialEfficacy outcome
In acromegaly patients, IGF-I with lanreotide at both assessment periods was similar to IGF-I with octreotide LAR.
In plain wordsIn acromegaly patients, IGF-I with lanreotide was similar to IGF-I with octreotide LAR.
Peptide
Lanreotide
Outcome
Direction not reportedIGF-I versus octreotide
Study
n: not reported in source
Comparator
octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 4-8 weeks · deep subcutaneous injectionAs given in this study (human).
Source sentences
Summary
Serum GH and IGF-I achieved at the end of Period 1 and Period 2 were similar to those reached with o-LAR.
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551106
08HumanNon-randomized trialEfficacy outcome
In acromegaly patients, GH < 2.5 microg/l occurred in 48% and 62% with lanreotide versus 43% with octreotide LAR.
In plain wordsIn acromegaly patients, GH control rates were comparable with lanreotide and octreotide LAR.
Peptide
Lanreotide
Outcome
Direction not reportedGH below threshold
Study
n: not reported in source
Comparator
octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 4-8 weeks · deep subcutaneous injectionAs given in this study (human).
Measurements
Patients with GH < 2.5 microg/l
43%
o-LAR
Patients with GH < 2.5 microg/l
48%
ATG120 Period 1
Patients with GH < 2.5 microg/l
62%
ATG120 Period 2
Source sentences
Summary
The number of patients who achieved GH < 2.5 microg/l was comparable between o-LAR (43%) and ATG120 at Period 1 (48%) and at Period 2 (62%).
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551107
09HumanNon-randomized trialEfficacy outcome
In acromegaly patients, normal IGF-I occurred in 11 patients (48%) and 10 (43%) with lanreotide versus 8 (35%) with octreotide LAR.
In plain wordsIn acromegaly patients, normal IGF-I rates were reported for lanreotide and octreotide LAR.
Peptide
Lanreotide
Outcome
Direction not reportedNormal IGF-I
Study
n: not reported in source
Comparator
octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 4-8 weeks · deep subcutaneous injectionAs given in this study (human).
Measurements
Patients with normal IGF-I
8 patients
during o-LAR
Patients with normal IGF-I
35%
during o-LAR
Patients with normal IGF-I
11 patients
ATG120 Period 1
Patients with normal IGF-I
48%
ATG120 Period 1
Patients with normal IGF-I
10 patients
ATG120 final visit
Patients with normal IGF-I
43%
ATG120 final visit
Source sentences
Summary
Normal IGF-I levels were recorded in 8 patients during o-LAR (35%), 11 during ATG Period 1 (48%) and 10 at the final visit (43%).
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551108
10HumanNon-randomized trialEfficacy outcome
In acromegaly patients, 4 responded better to lanreotide and 2 responded better to octreotide LAR.
In plain wordsIn acromegaly patients, some responded better to lanreotide and others to octreotide LAR.
Peptide
Lanreotide
Outcome
Direction not reportedIndividual treatment response
Study
n: not reported in source
Comparator
octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 mg every 4-8 weeks · deep subcutaneous injectionAs given in this study (human).
Measurements
Patients with better response to ATG120
4 patients
individual response comparison
Patients with better response to o-LAR
2 patients
individual response comparison
Source sentences
Summary
Last, 4 patients showed a better response to ATG120 and 2 to o-LAR.
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551109
11HumanNon-randomized trialEfficacy outcome
In acromegaly patients, GH with octreotide LAR was similar to GH with lanreotide at both assessment periods.
In plain wordsIn acromegaly patients, GH with octreotide LAR was similar to GH with lanreotide.
Peptide
Octreotide
Outcome
Direction not reportedGH versus lanreotide
Study
n: not reported in source
Comparator
lanreotide Autogel
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
every 4 weeks · 6-18 monthsAs given in this study (human).
Source sentences
Summary
Serum GH and IGF-I achieved at the end of Period 1 and Period 2 were similar to those reached with o-LAR.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks.
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551110
12HumanNon-randomized trialEfficacy outcome
In acromegaly patients, IGF-I with octreotide LAR was similar to IGF-I with lanreotide at both assessment periods.
In plain wordsIn acromegaly patients, IGF-I with octreotide LAR was similar to IGF-I with lanreotide.
Peptide
Octreotide
Outcome
Direction not reportedIGF-I versus lanreotide
Study
n: not reported in source
Comparator
lanreotide Autogel
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
every 4 weeks · 6-18 monthsAs given in this study (human).
Source sentences
Summary
Serum GH and IGF-I achieved at the end of Period 1 and Period 2 were similar to those reached with o-LAR.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks.
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551111
13HumanNon-randomized trialEfficacy outcome
In acromegaly patients, GH < 2.5 microg/l occurred in 43% with octreotide LAR versus 48% and 62% with lanreotide.
In plain wordsIn acromegaly patients, GH control rates were comparable with octreotide LAR and lanreotide.
Peptide
Octreotide
Outcome
Direction not reportedGH below threshold
Study
n: not reported in source
Comparator
lanreotide Autogel
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
every 4 weeks · 6-18 monthsAs given in this study (human).
Measurements
Patients with GH < 2.5 microg/l
43%
o-LAR
Patients with GH < 2.5 microg/l
48%
ATG120 Period 1
Patients with GH < 2.5 microg/l
62%
ATG120 Period 2
Source sentences
Summary
The number of patients who achieved GH < 2.5 microg/l was comparable between o-LAR (43%) and ATG120 at Period 1 (48%) and at Period 2 (62%).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks.
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551112
14HumanNon-randomized trialEfficacy outcome
In acromegaly patients, normal IGF-I occurred in 8 patients (35%) with octreotide LAR versus 11 (48%) and 10 (43%) with lanreotide.
In plain wordsIn acromegaly patients, normal IGF-I rates were reported for octreotide LAR and lanreotide.
Peptide
Octreotide
Outcome
Direction not reportedNormal IGF-I
Study
n: not reported in source
Comparator
lanreotide Autogel
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
every 4 weeks · 6-18 monthsAs given in this study (human).
Measurements
Patients with normal IGF-I
8 patients
during o-LAR
Patients with normal IGF-I
35%
during o-LAR
Patients with normal IGF-I
11 patients
ATG120 Period 1
Patients with normal IGF-I
48%
ATG120 Period 1
Patients with normal IGF-I
10 patients
ATG120 final visit
Patients with normal IGF-I
43%
ATG120 final visit
Source sentences
Summary
Normal IGF-I levels were recorded in 8 patients during o-LAR (35%), 11 during ATG Period 1 (48%) and 10 at the final visit (43%).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks.
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551113
15HumanNon-randomized trialEfficacy outcome
In acromegaly patients, 2 responded better to octreotide LAR and 4 responded better to lanreotide.
In plain wordsIn acromegaly patients, some responded better to octreotide LAR and others to lanreotide.
Peptide
Octreotide
Outcome
Direction not reportedIndividual treatment response
Study
n: not reported in source
Comparator
lanreotide Autogel
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
every 4 weeks · 6-18 monthsAs given in this study (human).
Measurements
Patients with better response to ATG120
4 patients
individual response comparison
Patients with better response to o-LAR
2 patients
individual response comparison
Source sentences
Summary
Last, 4 patients showed a better response to ATG120 and 2 to o-LAR.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks.
Summary · context
DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).
Summary · context
All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).
Report a problemFND-1755551114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00627796

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

Federico II Universityn = 27Jan 2003 to Dec 2007

Acromegaly

Trial page ClinicalTrials.govUpdated 3 Mar 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.